"Breakthrough Alzheimer's Drug Shows Promise Despite Side Effects"
TL;DR
Eli Lilly's stock is surging as its Alzheimer's treatment, donanemab, shows promising results in slowing cognitive decline, making it a strong competitor to Biogen's drug. The company is also bolstering its weight-loss drug portfolio with the acquisition of Versanis Bio. Analysts project strong earnings growth for Eli Lilly, with expectations of blockbuster sales for Mounjaro and donanemab in the coming years.
Topics:top-newsbusiness#alzheimers-treatment#biogen#business#earnings-growth#eli-lilly#weight-loss-drugs
- Eli Lilly Stock, IBD Stock Of The Day, Breaks Out With Tentpoles In Two Key Markets Investor's Business Daily
- US drugmaker: Alzheimer's development can be slowed down | DW News DW News
- Drug donanemab seen as turning point in dementia fight BBC
- Growing hope over a new Alzheimer's drug, but there are side effects CBC News: The National
- Pharmalittle: Data confirm benefits and risks of Lilly Alzheimer's drug; Medicare aims to pay hospitals to stockpile essential drugs STAT
Want the full story? Read the original reporting
Read on Investor's Business Daily